Publications by authors named "J J Isitt"
Aims/hypothesis: The aim of this study was to assess the long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring (rtCGM) with alert functionality compared with FreeStyle Libre 1 intermittently scanned continuous glucose monitoring (isCGM) without alerts in adults with type 1 diabetes in Belgium.
Methods: The IQVIA CORE Diabetes Model was used to estimate cost-effectiveness. Input data for the simulated baseline cohort were sourced from the randomised ALERTT1 trial (ClinicalTrials.
Article Synopsis
- Real-time continuous glucose monitoring (rt-CGM) leads to lower glycated hemoglobin (A1c) levels and reduced hypoglycemia compared to self-monitoring of blood glucose (SMBG) for insulin-treated Type 2 diabetes patients.
- An analysis of health and economic outcomes in Canada found that using rt-CGM resulted in higher lifetime costs (CAD 207,466) but also better quality-adjusted life expectancy (9.97 QALYs) compared to SMBG (CAD 189,863 and 9.02 QALYs, respectively).
- The incremental cost-utility ratio (ICUR) for rt-CGM was CAD 18,523 per QALY gained, suggesting that rt-CGM is likely a
Introduction: Real-time continuous glucose monitoring (rt-CGM) involves the measurement and display of glucose concentrations, potentially improving glucose control among insulin-treated patients with type 2 diabetes (T2D). The present analysis aimed to conduct a cost-effectiveness analysis of rt-CGM versus self-monitoring of blood glucose (SMBG) based on a USA retrospective cohort study in insulin-treated people with T2D adapted to the UK.
Methods: Long-term costs and clinical outcomes were estimated using the CORE Diabetes Model, with clinical input data sourced from a retrospective cohort study.
Introduction: Real-time continuous glucose monitoring (rt-CGM) allows patients with diabetes to adjust insulin dosing, potentially improving glucose control. This study aimed to compare the long-term cost-effectiveness of the Dexcom G6 rt-CGM device versus self-monitoring of blood glucose (SMBG) and flash glucose monitoring (FGM) in Australia in people with type 1 diabetes (T1D).
Methods: Long-term costs and clinical outcomes were estimated using the CORE Diabetes Model.